Evaluation of Safety and Exploratory Efficacy of CARTISTEM, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee

Trial Profile

Evaluation of Safety and Exploratory Efficacy of CARTISTEM, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Cartilage disorders; Knee injuries; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Medipost
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 May 2017 to 27 Jun 2017.
    • 18 Apr 2017 Planned primary completion date changed from 1 May 2016 to 27 Jun 2017.
    • 01 Jun 2015 Planned End Date changed from 1 Jun 2017 to 1 May 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top